Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-29

Clinical Trial Update: A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of PF-06650808 in advanced solid tumors; terminated with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PF-06650808 (PF-06650808)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-03-29